Quantcast

Latest Hepatocellular carcinoma Stories

2014-07-15 08:28:28

Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5(th) Asia-Pacific Primary Liver...

2014-07-10 08:27:12

Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer drug; The global liver cancer drug market is expected to exceed $2 billion by 2015 PETACH TIKVA, Israel, July 10, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli...

2014-07-09 23:00:57

July 28th is designated as World Hepatitis Day by the World Health Organization, and Narconon Arrowhead is releasing information on hepatitis prevention to help raise awareness of viral hepatitis, and the need for better prevention programs. Canadian, Oklahoma (PRWEB) July 09, 2014 Narconon Arrowhead, the Oklahoma-based successful alcohol & drug rehabilitation center, will be releasing information on hepatitis and its prevention in support of World Hepatitis Day. Viral hepatitis is...

2014-07-09 11:33:39

The Mount Sinai Hospital / Mount Sinai School of Medicine Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature. A team led by the Icahn School of Medicine at Mount Sinai and Harvard Medical School has discovered a link between the presence of two mutant proteins IDH1 and IDH2 and cancer. Past studies have found IDH...

2014-07-08 12:29:16

Australia Has the Strongest Presence of These Innovative Products, But Competitors Are Increasingly Focusing on China, According to Findings from Decision Resources Group BURLINGTON, Mass., July 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the Asia Pacific market for transcatheter embolization and occlusion (TEO) devices--including Australia, China, South Korea and India--is a dynamic and fast-growing market, driven by the launch of novel products such as interventional...

2014-07-07 08:27:57

Clinical Activity of G-202 to be presented at session for Treatment for Intermediate-Advanced Stage Disease SAN ANTONIO, July 7, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13(th)...

2014-07-07 08:27:35

ROCKVILLE, Md., July 7, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). http://photos.prnewswire.com/prnvar/20140706/124566...

2014-07-07 08:22:14

-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase III DECISION trial TORONTO, July 7, 2014 /CNW/ - Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally...

2014-07-02 12:13:46

The JAMA Network Journals Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies. The drug sorafenib is the only systemic therapy shown to significantly improve...

2014-07-01 12:27:54

- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir(TM) with Ribavirin(TM) in Genotype 1, Therapy Naive HCV Patients. LOS ANGELES, July 1, 2014 /PRNewswire/ -- Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM)...


Latest Hepatocellular carcinoma Reference Libraries

Hepatitis B
2013-02-25 09:11:23

Image Caption: This electron micrograph reveals the presence of hepatitis-B virus HBV "Dane particles", or virions. Credit: CDC/Wikipedia Hepatitis B: What Is It? Hepatitis simply means a swelling or inflammation of the liver. The type hepatitis that a person contracts (there are 5 common forms) affects their long-term prognosis. The most common and most severe of these different types of liver infection is Hepatitis B, which is caused by the hepatitis B virus (HBV). It is typically...

45_36624a455e3cd9a4152b7670308f0ffa
2011-01-20 19:14:56

Hepatitis B virus, HBV, is a part of the Hepadnaviridae family of viruses. HBV can lead to cirrhosis and hepatocellular carcinoma and has been linked to pancreatic cancer. It is classified as a species of the Orthohepadnavirus. Similar viruses have been found worldwide in great apes and monkeys. There a few different genotypes and they all differ by at least 8% of the sequence and have distinct geographical distributions and this has been associated with anthropological history. Type A is...

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (3 articles) »
Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'